An unexpected partnership targeting FLT3wt AML

Blood. 2022 Dec 15;140(24):2529-2530. doi: 10.1182/blood.2022017344.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Bridged Bicyclo Compounds, Heterocyclic
  • Humans
  • Leukemia, Myeloid, Acute* / genetics
  • Leukemia, Myeloid, Acute* / therapy
  • Myeloid Cell Leukemia Sequence 1 Protein
  • fms-Like Tyrosine Kinase 3 / genetics

Substances

  • venetoclax
  • gilteritinib
  • Myeloid Cell Leukemia Sequence 1 Protein
  • Bridged Bicyclo Compounds, Heterocyclic
  • FLT3 protein, human
  • fms-Like Tyrosine Kinase 3